Managing Adverse Events in Patients With Metastatic Melanoma Receiving First-Line Systemic Therapy

In an interview, Vincent Law, of Moffitt Cancer Center, discussed a new study that offers hope for patients with melanoma brain metastasis.

In this episode of Targeted Talks, Omid Hamid, MD, discusses data supporting the use of lifileucel for the treatment of advanced melanoma.

Meredith McKean, MD, MPH, discussed findings from a longer-term follow-up study evaluating fianlimab plus cemiplimab for the treatment of metastatic melanoma.

In season 4, episode 4 of Targeted Talks, Richard D. Carvajal, MD, discusses mucosal melanoma and treatment options for the disease.

TH17 cells may be a potential biomarker to predict the risk of immune-related adverse events in patients with metastatic melanoma receiving the combination therapy of nivolumab, ipilimumab, and tocilizumab.

During a Case-Based Roundtable® event, Ahmad Tarhini, MD, PhD, discussed the 2024 update to the RELATIVITY-047 trial in advanced melanoma in the first article of a 2-part series.